Nov 09, 2022
EMERYVILLE, Calif. , Nov. 9, 2022 /PRNewswire/ --  Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that Ryan Spencer , Chief Executive Officer, and Kelly MacDonald , Chief Financial
Nov 03, 2022
Q3 2022 total revenue of $167.7 million , up 55% from $108.3 million for Q3 2021 HEPLISAV-B ®  vaccine net product revenue of $37.5 million, up 65% from $22.7 million for Q3 2021 CpG 1018 ® adjuvant net product revenue of $126.3 million , up 50% from $84.3 million for Q3 2021 Reiterates guidance
Aug 04, 2022
Q2 2022 total revenue of $256.5 million , up 386% from $52.8 million for Q2 2021 HEPLISAV-B ®  vaccine net product revenue of $32.7 million, up 139% from $13.7 million for Q2 2021 CpG 1018 ® adjuvant net product revenue of $222.6 million , up 471% from $39.0 million for Q2 2021 On track for second